Oryzon Genomics Participation at the Phelan-McDermid Syndrome Congress
Oryzon Genomics, a prominent player in the biopharmaceutical field, has exciting news that it will be present at the upcoming Phelan-McDermid Syndrome Congress. This established event runs from June 26 to June 29 in Barcelona, bringing together experts and stakeholders to discuss pressing issues surrounding this rare genetic condition.
Industry Perspectives Discussion on June 27
At this significant gathering, Dr. Jordi Xaus, Chief Scientific Officer of Oryzon, will represent the company on June 27 in a panel known as the “Industry Perspectives Discussion.” This thoughtful panel aims to delve deeply into various aspects of industry involvement in clinical trials and business considerations relating to noncommercial and commercial efforts in the therapeutic landscape.
Insights into Phelan-McDermid Syndrome
Phelan-McDermid Syndrome (PMS) predominantly affects individuals with features commonly associated with autism spectrum disorders (ASD), with studies indicating that between 70% to 90% of affected individuals display autistic traits, including aggression. Addressing these challenges, Oryzon is actively involved in the VANDAM project, which seeks to tackle agitation and aggression in PMS and other ASD-related subpopulations.
Oryzon’s Commitment as a Congress Sponsor
Oryzon is proud to participate not just as an attendee but as a sponsor of this important congress. Their engagement highlights the company’s commitment to the scientific community as well as to families, healthcare professionals, and researchers involved in these discussions. The congress includes two key events: the CureSHANK’s 2nd Annual Phelan-McDermid Syndrome Drug Development Symposium and the III Scientific Conference of the Spanish Phelan-McDermid Syndrome Association.
Exploring Therapeutic Advances
Oryzon’s innovative work focuses on vafidemstat, an LSD1 inhibitor designed to address central nervous system disorders. This compound is not only being researched for PMS and other ASD-related indications but also has shown promise in Phase IIb trials with Borderline Personality Disorder patients, demonstrating its potential in reducing key symptoms like agitation and aggression. A recent trial even detailed its efficacy across various psychiatric disorders, underscoring the potential of vafidemstat as a vital tool in treatment.
Collaboration for Enhanced Research
The company’s dedication to advancing research is evident through its collaboration with esteemed institutions, including the Medical and Molecular Genetics Institute and the Research Institute La Paz Hospital in Madrid. This collaboration aims to enhance our understanding of PMS, leading to more effective and targeted treatments for individuals affected by this condition.
Funding and Future Directions
Oryzon has secured substantial funding, receiving €13.5 million through the Important Project of Common European Interest (IPCEI) for its VANDAM project. This funding is empowering the organization to explore personalized medicine approaches within the realm of rare diseases. Through these efforts, Oryzon aims to validate the use of epigenetic drugs like vafidemstat, setting the groundwork for therapeutic applications that could significantly impact the lives of patients.
About Oryzon Genomics
Founded in 2000, Oryzon Genomics has established itself as a leader in epigenetics within the biopharmaceutical sector. With a strong emphasis on personalized medicine targeting CNS disorders and oncology, Oryzon continues to develop innovative treatments guided by a talented team located in major hubs like Barcelona, Boston, and San Diego. Their robust pipeline includes vafidemstat, which is nearing Phase III readiness, and iadademstat, aimed at treating various cancer types.
A Vision for the Future
With ongoing clinical trials investigating the use of vafidemstat in various conditions, Oryzon is well-positioned to advance new treatment paradigms. Their efforts to explore CNS precision medicine highlight the ambition to bring transformative changes to how we approach genetic disorders and related conditions.
Frequently Asked Questions
1. What is Oryzon Genomics’ role in the Phelan-McDermid Syndrome Congress?
Oryzon Genomics will participate as a sponsor and feature its Chief Scientific Officer, Dr. Jordi Xaus, in a panel discussion.
2. What key topics will Dr. Xaus address at the congress?
Dr. Xaus will discuss industry perspectives on clinical trials related to Phelan-McDermid Syndrome during his panel discussion.
3. What is vafidemstat, and how does it relate to psychiatric disorders?
Vafidemstat is an LSD1 inhibitor being explored for its ability to reduce agitation and aggression in various psychiatric disorders, showing promise in clinical trials.
4. How does Oryzon ensure collaboration in research?
Oryzon collaborates with reputable research institutions to enhance the understanding and treatment of PMS and related disorders.
5. What funding has Oryzon secured for its research efforts?
Oryzon has obtained €13.5 million through the EU's IPCEI initiative, supporting innovative projects like VANDAM in personalized medicine.
